Accueil » Communiqués de presse » Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor.
Les communiqués de presse
14Jun2022
Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor.
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
